Home » Thought Leadership » Page 2

Thought Leadership

Read our insights and commentary about industry news and innovation globally. Subscribe to our monthly newsletter to keep up to date with our thought leadership, news, and updates.

Showing 5 of 30 posts
THE RESULTANT IMPACT OF HEOR DATA ON US PAYER FORMULARY COVERAGE WEB
May 18, 2020 | Research posters

ISPOR Annual 2020: The Resultant Impact of HEOR Data on US Payer Formulary Coverage

A research poster identifying instances where manufacturer HEOR data and/or pharmacoeconomic models either influenced positive changes, or had limited tangible impact on resultant US payer coverage decisions.

May 13, 2020 | Podcasts

Speaking of Access: The Management of Gene Therapies (Now and in the Future)

Andrew Gould asks our US payer panel for their expert perspectives surrounding the management of gene therapies, both now and in the future.

May 7, 2020 | Podcasts

CBPartners’ Pharma Take-Away: AMARIN’s VASCEPA patent loss: is it obvious(ness)?

Patent management is the hot topic of this episode. The focus is on AMARIN’s leading product, VASCEPA, a drug made up of natural derivatives such as fish oil and was approved by the FDA in December 2019.

May 5, 2020 | Podcasts

Speaking of Access: Pricing for Uncertain Indications

Andrew Gould asks our US payer panel for their expert perspectives surrounding pricing for uncertain future indications.

tumour case study
March 24, 2020 | Blog

Tumor-Agnostic Therapies: The Complex Path to Commercial Viability

The tumor-agnostic space is incredibly exciting and an area that is likely to be explored further. CBPartners’ blog post addresses the current precision medicine landscape, touching upon challenges, as well as key commercial considerations.